This closing forms a natural continuum following the €7.6 million France 2030 i-Démo grant announced last year, and the very ...

Generation Bio will exit its Kendall Square headquarters since 2018 following its acquisition by an aggregator of drug royalty rights.

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of 2020 and 2021 and an anticipated stock recovery in 2024 failed to materialise.

When Neal Piper’s son, Noah, rang the bell at UVA Children’s Hospital in December 2020, it signaled the end of grueling chemotherapy treatments connected to beeping monitors and intravenous tubes.

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug ...

Moving Biotech (4MB), a clinical-stage biotechnology company and a spin-off of 4P-Pharma, developing a first-in-class disease-modifying osteoarthritis drug (DMOAD) for knee osteoarthritis, today ...